Skip to main content

Emergent BioSolutions

Protecting You From Public Health Threats

Our mission is to protect and enhance life

Emergent BioSolutions

Prepare. Prevent. Protect.

video link

We make medical countermeasures that address natural, accidental and intentional public health threats. Our products target biological and chemical threats, as well as emerging infectious diseases. 

Fighting Emerging Infectious Diseases

Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus

Strengthening Our Anthrax Franchise

Emergent BioSolutions Completes Acquisition of Raxibacumab from GlaxoSmithKline

Expanding Our Portfolio of Medical Countermeasures

Emergent BioSolutions Completes Acquisition of ACAM2000 Vaccine Business from Sanofi

FDA Approves Manufacturing of ACAM2000 at Canton, Massachusetts Facility

ACAM2000 is the Only FDA-Licensed Smallpox Vaccine 

Explore more stories Scroll down